Leili Aghebati‐Maleki

8.8k citations

219 papers · 6.4k indexed · 2 hit papers · h-index 47

Molecular Biology top 5%
Immunology top 1%
Oncology top 5%
Public Health, Environmental and Occupational Health top 2%
Obstetrics and Gynecology top 1%

Co-authors: Mehdi Yousefi Ali Aghebati‐Maleki Majid Ahmadi Behzad Baradaran Sanam Dolati Hossein Samadi Kafil Amin Abbasi Mohammad Nouri
Topics: Reproductive System and Pregnancy (51 papers)Monoclonal and Polyclonal Antibodies Research (27 papers)Immunotherapy and Immune Responses (22 papers)
Cited by: Immunology Obstetrics and Gynecology Reproductive Medicine
Journals: SHILAP Revista de lepidopterologíaScientific Reports International Journal of Molecular Sciences
Partner nations: Iran Sweden Hungary

In The Last Decade

Leili Aghebati‐Maleki

202 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancers

2019 328 citations Ali Aghebati‐Maleki, Sanam Dolati et al. Journal of Cellular Physiology profile →
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

2023 124 citations Amirhossein Mardi, Ali Aghebati‐Maleki et al. profile →

Peers

Countries citing papers authored by Leili Aghebati‐Maleki

Since Specialization

Citations

This map shows the geographic impact of Leili Aghebati‐Maleki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leili Aghebati‐Maleki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leili Aghebati‐Maleki more than expected).

Fields of papers citing papers by Leili Aghebati‐Maleki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leili Aghebati‐Maleki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leili Aghebati‐Maleki. The network helps show where Leili Aghebati‐Maleki may publish in the future.

Co-authorship network of co-authors of Leili Aghebati‐Maleki

This figure shows the co-authorship network connecting the top 25 collaborators of Leili Aghebati‐Maleki. A scholar is included among the top collaborators of Leili Aghebati‐Maleki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leili Aghebati‐Maleki. Leili Aghebati‐Maleki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunoglobulin therapy for infertility and the role of immune cells in pregnancy success: An extensive investigation and update 2025 ·Journal of Reproductive Immunology ·(unknown),(unknown),Mohammad Sadegh Soltani‐Zangbar,Amirhossein Mardi,Leili Aghebati‐Maleki	1
2	The effect of vitamin D supplementation and vaginal probiotics on fertility in women with recurrent implantation failure: A randomized clinical trial 2025 ·Human Immunology ·(unknown),Parisa Sharifi,Amir Moradi,Amin Kamrani,Ali Hassanzadeh,Mohammad Sadegh Soltani‐Zangbar,(unknown),(unknown),Javad Ahmadian Heris,Shahla Danaii,(unknown),(unknown),(unknown),(unknown),Leili Aghebati‐Maleki,Mehdi Yousefi	2
3	The crosstalk between MiRNAs and autophagy in leukemia: mechanisms and therapeutic insights 2025 ·Discover Oncology ·(unknown),Ali Akbari,Leili Aghebati‐Maleki,Sanam Dolati,Mehdi Yousefi	0
4	The effectiveness of ruxolitinib and cyclophosphamide combination on T helper 17 and regulatory T cells in rat experimental membranous glomerulonephritis 2024 ·Molecular and Cellular Probes ·(unknown),Maryam Hosseini,Mahdi Bagheri,Mohammad Sadegh Soltani‐Zangbar,(unknown),(unknown),(unknown),Arash Khaki,Leili Aghebati‐Maleki,Leila Roshangar,(unknown),(unknown),(unknown),Ali Akbar Shekarchi,Javad Ahmadian Heris,Jalal Etemadi,Mehdi Yousefi	0
5	CTLA-4 silencing could promote anti-tumor effects in hepatocellular 2024 ·Medical Oncology ·Amirhossein Mardi,(unknown),(unknown),Amir Baghbanzadeh,(unknown),(unknown),Siamak Sandoghchian Shotorbani,(unknown),Leili Aghebati‐Maleki	0
6	Boosting immunotherapy efficacy: Empowering the Potency of Dendritic cells loaded with breast cancer lysates through CTLA-4 suppression 2024 ·Heliyon ·(unknown),Javad Masoumi,Farid Ghorbaninezhad,Leili Aghebati‐Maleki,(unknown),Siamak Sandoghchian Shotorbani,Farhad Jadidi‐Niaragh,Amir Baghbanzadeh,Nima Hemmat,Elham Baghbani,Amir Ghaffari Jolfayi,Behzad Baradaran	2
7	SARS-CoV2 infection induce miR-155 expression and skewed Th17/Treg balance by changing SOCS1 level: A clinical study 2023 ·Cytokine ·Mohammad Sadegh Soltani‐Zangbar,Mahsa Hajivalili,(unknown),(unknown),(unknown),(unknown),Leili Aghebati‐Maleki,(unknown),(unknown),Naser Amini,Amir Mehdizadeh,(unknown),Ata Mahmoodpoor,Javad Ahmadian Heris,Mehdi Yousefi	14
8	Autophagy-mediated immune system regulation in reproductive system and pregnancy-associated complications 2023 ·Journal of Reproductive Immunology ·(unknown),Forough Parhizkar,Samaneh Abdolmohammadi‐Vahid,(unknown),(unknown),Mehdi Yousefi,Leili Aghebati‐Maleki	7
9	Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives 2022 ·Cell Communication and Signaling ·Mohammad Sadegh Soltani‐Zangbar,Forough Parhizkar,(unknown),Navid Shomali,Leili Aghebati‐Maleki,(unknown),Leila Roshangar,Ata Mahmoodpoor,Mehdi Yousefi	12
10	Evaluating the effects of autologous platelet lysate on gene expression of bone growth factors and related cytokines secretion in rabbits with bone fracture 2022 ·Gene Reports ·(unknown),Farzaneh Ghorbani,Majid Ahmadi,Ali Aghebati‐Maleki,Sanaz Abbaspour‐Aghdam,Ali Fotouhi,Majid Zamani,(unknown),Mansour Khakpour,Leili Aghebati‐Maleki	1
11	Postbiotics, as Dynamic Biomolecules, and Their Promising Role in Promoting Food Safety 2021 ·Biointerface Research in Applied Chemistry ·Aziz Homayouni Rad,Leili Aghebati‐Maleki,Hossein Samadi Kafil,Neda Gilani,Amin Abbasi,Nader Khani,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	55
12	Antifungal Effects of Voriconazole-Loaded Nano-Liposome on Fluconazole - Resistant Clinical Isolates of Candida albicans , Biological Activity and ERG11, CDR1, and CDR2 Gene Expression 2021 ·Assay and Drug Development Technologies ·(unknown),Hamed Hamishehkar,(unknown),Behzad Baradaran,Siamak Sandoghchian Shotorbani,Maryam Mohammadi,Navid Shomali,Leili Aghebati‐Maleki,Sanam Nami	12
13	Antibacterial, Antiviral, Antioxidant, and Anticancer Activities of Postbiotics: A review of Mechanisms and Therapeutic Perspectives 2021 ·Biointerface Research in Applied Chemistry ·Leili Aghebati‐Maleki,(unknown),Amin Abbasi,Nader Khani,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	61
14	The Application of Next Generation Sequencing in Phage Display: A Short Review 2021 ·SHILAP Revista de lepidopterología ·Ali Aghebati‐Maleki,Behzad Baradaran,Khalil Hajiasgharzadeh,Babak Bakhshinejad,Leili Aghebati‐Maleki	0
15	Postbiotics as Promising Tools for Cancer Adjuvant Therapy 2020 ·Advanced Pharmaceutical Bulletin ·Aziz Homayouni Rad,Leili Aghebati‐Maleki,Hossein Samadi Kafil,(unknown),Amin Abbasi	60
16	Oxidative stress, inflammatory settings, and microRNA regulation in the recurrent implantation failure patients with metabolic syndrome 2019 ·American Journal of Reproductive Immunology ·(unknown),Mohammad Sadegh Soltani‐Zangbar,(unknown),Amin Kamrani,Ramyar Azizi,Leili Aghebati‐Maleki,Shahla Danaii,(unknown),Mohammad Hojjat‐Farsangi,Mehdi Yousefi	43
17	The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia 2018 ·Journal of Cellular Physiology ·Shadi Eghbal‐Fard,Mehdi Yousefi,(unknown),Majid Ahmadi,(unknown),(unknown),Farhad Jadidi‐Niaragh,Bahman Yousefi,Sanam Dolati,Mohammad Hojjat‐Farsangi,Reza Rikhtegar,Mohammad Nouri,Leili Aghebati‐Maleki	106
18	Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells 2018 ·Advanced Pharmaceutical Bulletin ·Naime Majidi Zolbanin,Reza Jafari,Jafar Majidi,Fatemeh Atyabi,Mehdi Yousefi,Farhad Jadidi‐Niaragh,Leili Aghebati‐Maleki,Dariush Shanehbandi,Mohammad Sadegh Soltani‐Zangbar,Alireza Mohajjel Nayebi	25
19	Polyclonal Antibody Production against Mouse Purified IgG2a towards Use in Basic Research 2016 ·SHILAP Revista de lepidopterología ·(unknown),Jafar Majidi,Leili Aghebati‐Maleki,Tohid Kazemi,Jalal Abdolalizadeh,(unknown),(unknown),Majid Ahmadi,(unknown)	2
20	Generation and Characterization of Anti-CD34 Monoclonal Antibodies that React with Hematopoietic Stem Cells 2014 ·SHILAP Revista de lepidopterología ·Leili Aghebati‐Maleki,Jafar Majidi,Behzad Baradaran,Ali Akbar Movassaghpour,Jalal Abdolalizadeh	6

About Leili Aghebati‐Maleki

Leili Aghebati‐Maleki is a scholar working on Immunology, Reproductive Medicine and Obstetrics and Gynecology, having authored 219 papers that have together received 6.4k indexed citations. Recurring topics across this work include Reproductive System and Pregnancy (51 papers), Monoclonal and Polyclonal Antibodies Research (27 papers) and Immunotherapy and Immune Responses (22 papers). The work is most often cited by research in Immunology (1.9k citations), Obstetrics and Gynecology (652 citations) and Reproductive Medicine (627 citations). Leili Aghebati‐Maleki has collaborated with scholars based in Iran, Sweden and Hungary. Frequent co-authors include Mehdi Yousefi, Ali Aghebati‐Maleki, Majid Ahmadi, Behzad Baradaran, Sanam Dolati, Hossein Samadi Kafil, Amin Abbasi, Mohammad Nouri, Jafar Majidi and Farhad Jadidi‐Niaragh. Their work appears in journals such as SHILAP Revista de lepidopterología, Scientific Reports and International Journal of Molecular Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact